Compare ResMed Inc. (RMD) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Xylem, Inc. — how do they compare? ResMed Inc. trades at $230.96 (market cap $31.89B), while Xylem, Inc. trades at $102.2 (market cap $23.81B). The key difference: ResMed Inc. is the larger of the two by market cap, and Xylem, Inc. pays the higher dividend (1.69%). Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Xylem, Inc. for 50 Days on average.
| RMD | XYL | |
|---|---|---|
Market Cap | $31.89B | $23.81B |
Volume | 618,314 | 2,234,713 |
Sector | Health | Industrials |
52-Week High | $277.88 | $152.95 |
52-Week Low | $182.82 | $100.92 |
Typical Hold Time | 51 Days | 50 Days |
Enterprise Value | $31.24B | $25.59B |
Dividend Yield | 1.16% | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
Xylem (XYL) trades at $102.20, up 0.36% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results due October 27, 2026. Revenue grew to $9.04B in 2025, with a net income margin of 10.59%, while recent acquisitions like Cornell Pump and Roper Pump aim to strengthen its industrial water solutions presence.
The outlook is supported by steady revenue growth and margin expansion, but risks include China weakness and higher debt from recent note offerings. Analyst consensus is mixed with a $149.13 price target, suggesting potential upside, though technical indicators caution near-term pressure. Investment appeal hinges on execution of growth strategies amid competitive and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
